SynthesisDeutsches Arzteblatt international2020
Schizophrenia.
Synthesis in Deutsches Arzteblatt international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Guideline
- Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis.The British journal of psychiatry : the journal of mental science · 2026Pooled it
- Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials.JAMA psychiatry · 2021Pooled it
- Effectiveness of adjunctive traditional Chinese medicine in reducing psychiatric rehospitalization in patients with schizophrenia: A nationwide cohort study in Taiwan.Integrative medicine research · 2026Article
- Heterogeneity of composite inflammatory markers in acute schizophrenia: stratification by age, gender, and age at onset.European archives of psychiatry and clinical neuroscience · 2026Article
- Changes of psychological and biological stress parameters in individuals with schizophrenia spectrum disorders participating in a mindfulness-based group therapy.Schizophrenia (Heidelberg, Germany) · 2026Article
- Diagnosis and management of cognitive impairment associated with schizophrenia: Real-world evidence from a cross-sectional survey of psychiatrists.Schizophrenia research. Cognition · 2026Article
- Schizophrenia and catatonia: from ICD-10 to ICD-11.Der Nervenarzt · 2025Article
- [Schizophrenia and catatonia: from ICD-10 to ICD-11. German version].Der Nervenarzt · 2025Review
- Article
- The diagnostic potential of unconjugated bilirubin in schizophrenia and bipolar disorder.BMC psychiatry · 2025Article
- Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Developing the EPA guidance of pharmacological treatment of schizophrenia - results of a Delphi process.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Changes in the ability to correctly identify schizophrenia and depression: results from general population surveys in Germany over 30 years.Social psychiatry and psychiatric epidemiology · 2024Article
- Exploring the interplay of psychiatric symptoms, antipsychotic medications, side effects, employment status, and quality of life in Chronic Schizophrenia.BMC psychiatry · 2024Article
- Article
- Article
- Cariprazine and clozapine combination for the treatment of psychosis in a young, female patient with schizophrenia: a case report.Frontiers in psychiatry · 2024Article
- Blood-brain barrier dysfunction and folate and vitamin B12 levels in first-episode schizophrenia-spectrum psychosis: a retrospective chart review.European archives of psychiatry and clinical neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lifetime prevalence of schizophrenia is 1%. Schizophrenia is among the most severe mental illnesses and gives rise to the highest treatment costs per patient of any disease. It is characterized by frequent relapses, marked impairment of quality of life, and reduced social and work participation.
methodsThe group entrusted with the creation of the German clinical practice guideline was chosen to be representative and pluralistic in its composition. It carried out a systematic review of the relevant literature up to March 2018 and identified a total of 13 389 publications, five source guidelines, three other relevant German clinical practice guidelines, and four reference guidelines.
resultsAs the available antipsychotic drugs do not differ to any great extent in efficacy, it is recommended that acute antipsychotic drug therapy should be sideeffect- driven, with a number needed to treat (NNT) of 5 to 8. The choice of treatment should take motor, metabolic, sexual, cardiac, and hematopoietic considerations into account. Ongoing antipsychotic treatment is recommended to prevent relapses (NNT: 3) and should be re-evaluated on a regular basis in every case. It is also recommended, with recommendation grades ranging from strong to intermediate, that disorder- and manifestation-driven forms of psychotherapy and psychosocial therapy, such as cognitive behavioral therapy for positive or negative manifestations (effect sizes ranging from d = 0.372 to d = 0.437) or psycho-education to prevent relapses (NNT: 9), should be used in combination with antipsychotic drug treatment. Further aspects include rehabilitation, the management of special treatment situations, care coordination, and quality management. A large body of evidence is available to provide a basis for guideline recommendations, particularly in the areas of pharmacotherapy and cognitive behavioral therapy.
conclusionThe evidence-based diagnosis and treatment of persons with schizophrenia should be carried out in a multiprofessional process, with close involvement of the affected persons and the people closest to them.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.